Risk of Colorectal Cancer Linked to Composition of the Gut Microbiome
|
By LabMedica International staff writers Posted on 17 Dec 2013 |
The composition of the community of bacteria living in the digestive tract has been linked to the risk of developing colorectal cancer (CRC).
Colorectal cancer is diagnosed in about 143,000 Americans annually with nearly 51,000 fatalities, making it second only to lung cancer in the number of deaths caused each year. However, it is not well understood why colorectal cancer develops.
Investigators at the New York University School of Medicine (NY, USA) tested the hypothesis that an altered community of gut microbes was associated with risk of developing CRC. To this end, they compared the DNA composition of intestinal microbes in the stool samples of 47 CRC patients and 94 healthy volunteers.
16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by Roche (Basel, Switzerland) 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME protocol.
QIIME, which stands for Quantitative Insights into Microbial Ecology, is an open source software package for comparison and analysis of microbial communities, primarily based on high-throughput amplicon sequencing data generated on a variety of platforms, but also supporting analysis of other types of data. QIIME chaperones users from their raw sequencing output through initial analyses such as OTU (operational taxonomic unit) picking, taxonomic assignment, and construction of phylogenetic trees from representative sequences of OTUs, and through downstream statistical analysis, visualization, and production of publication-quality graphics. QIIME has been applied to studies based on billions of sequences from thousands of samples.
Taxonomic differences identified in this study were confirmed by quantitative polymerase chain reaction (qPCR) and adjusted for false discovery rate. Data from 794,217 16S rRNA gene sequences revealed that CRC case subjects had decreased overall microbial community diversity. In taxonomy-based analyses, lower relative abundance of Clostridia and increased carriage of Fusobacterium and Porphyromonas were found in case subjects compared with control subjects. Clostridia include some bacterial family members that ferment dietary fiber to butyrate, which is a major colonic metabolite that may inhibit inflammation and carcinogenesis in the colon, while Fusobacterium and Porphyromonas are related to inflammation in the mouth and gastrointestinal track.
"Our findings are important because identification of these microbes may open the door for colorectal cancer prevention and treatment," said first author Dr. Jiyoung Ahn, assistant professor of population health at the New York University School of Medicine. "Our next step is to study how diet and lifestyle factors modulate these gut bacteria associated with colorectal cancer. This may lead to ways to prevent this disease."
The paper was published in the December 6, 2013, online edition of the Journal of the [US] National Cancer Institute.
Related Links:
New York University School of Medicine
Roche
QIIME
Colorectal cancer is diagnosed in about 143,000 Americans annually with nearly 51,000 fatalities, making it second only to lung cancer in the number of deaths caused each year. However, it is not well understood why colorectal cancer develops.
Investigators at the New York University School of Medicine (NY, USA) tested the hypothesis that an altered community of gut microbes was associated with risk of developing CRC. To this end, they compared the DNA composition of intestinal microbes in the stool samples of 47 CRC patients and 94 healthy volunteers.
16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by Roche (Basel, Switzerland) 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME protocol.
QIIME, which stands for Quantitative Insights into Microbial Ecology, is an open source software package for comparison and analysis of microbial communities, primarily based on high-throughput amplicon sequencing data generated on a variety of platforms, but also supporting analysis of other types of data. QIIME chaperones users from their raw sequencing output through initial analyses such as OTU (operational taxonomic unit) picking, taxonomic assignment, and construction of phylogenetic trees from representative sequences of OTUs, and through downstream statistical analysis, visualization, and production of publication-quality graphics. QIIME has been applied to studies based on billions of sequences from thousands of samples.
Taxonomic differences identified in this study were confirmed by quantitative polymerase chain reaction (qPCR) and adjusted for false discovery rate. Data from 794,217 16S rRNA gene sequences revealed that CRC case subjects had decreased overall microbial community diversity. In taxonomy-based analyses, lower relative abundance of Clostridia and increased carriage of Fusobacterium and Porphyromonas were found in case subjects compared with control subjects. Clostridia include some bacterial family members that ferment dietary fiber to butyrate, which is a major colonic metabolite that may inhibit inflammation and carcinogenesis in the colon, while Fusobacterium and Porphyromonas are related to inflammation in the mouth and gastrointestinal track.
"Our findings are important because identification of these microbes may open the door for colorectal cancer prevention and treatment," said first author Dr. Jiyoung Ahn, assistant professor of population health at the New York University School of Medicine. "Our next step is to study how diet and lifestyle factors modulate these gut bacteria associated with colorectal cancer. This may lead to ways to prevent this disease."
The paper was published in the December 6, 2013, online edition of the Journal of the [US] National Cancer Institute.
Related Links:
New York University School of Medicine
Roche
QIIME
Latest Molecular Diagnostics News
- Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
- Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
- Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
- Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
- Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
- Tumor Genomic Testing Guides Immunotherapy Selection in Pituitary Tumors
- Liquid Biopsy Predicts Immunotherapy Response in Breast Cancer
- New Blood Test Distinguishes Pancreatic Cancer From Benign Disease
- Noninvasive Test Confirms High-Risk Prenatal Screening Results from Blood
- Machine-Learning Genetic Risk Score Improves Early Prediction of Type 1 Diabetes
- Rapid Tongue Swab Molecular Test Detects Pulmonary Tuberculosis at Point of Care
- CRISPR-Based Test Identifies Multiple Respiratory Viruses Simultaneously
- Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder
- Portable Test Detects Tuberculosis from Tongue Swabs in 30 Minutes
- Multi-Omic Assay Predicts Recurrence and Radiation Benefit in Early Breast Cancer
- Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








